Skip to main content

Advertisement

Table 1 Demographic, social, and clinical characteristics of women by HPV genotype result

From: A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil

  No HPV Only low risk HPV One high risk HPV More than one high risk HPV Total
N (%) 64 (11.4) 134 (23.8) 183 (32.6) 181 (32.2) 562
Age in years, median (IQR) 37.4 (30.3–41.3) 38.5 (31.1–45.5) 36.0 (29.9–44.0) 32.7 (26.5–41.3)a 35.8 (29.3–43.6)
Non-white race, n (%) 50 (79.4) 99 (73.9) 129 (71.3) 124 (68.9) 402 (72.0)
Years of formal education, median (IQR) 8 (5–11) 8 (5–11) 8 (5–11) 9 (6–11)b 8 (5–11)
Monthly income (US$), median (IQR) 400 (255–600) 425 (250–750) 400 (232.5–750) 450 (232.5–800) 415 (235–750)
Married/living with partner, n (%) 34 (53.1) 85 (63.4) 100 (54.6) 102 (56.4) 321 (57.1)
Age at sexual debut, median (IQR) 16 (14–18) 16 (15–18) 16 (15–18) 16 (15–18) 16 (15–18)
Number of lifetime sexual partners, median (IQR) 5 (4–12) 5 (3–8) 5 (3–10) 5 (3–9) 5 (3–10)
Condom use with last sexual intercourse, n (%) 37 (57.8) 86 (65.7) 117 (65.4) 118 (66.3) 358 (64.9)
HIV-infected current sexual partner, n (%) 9 (14.1) 38 (28.4)c 28 (15.3) 50 (27.6)c, d 125 (22.2)
Number of pregnancies, median (IQR) 2 (1–4) 3 (2–4) 3 (1–4) 2 (1–3)a 2 (1–4)
Current hormonal contraceptive use, n (%) 16 (25.0) 19 (14.3) 27 (14.8) 33 (18.2) 95 (17.0)
Current tobacco usee, n (%) 10 (15.6) 37 (20.6) 36 (20.2) 31 (23.1) 114 (20.5)
Nadir CD4+ lymphocyte countf, median (IQR) 302 (190–570) 307 (155–500) 255 (128–483) 256 (90–414)b 274 (128–467)
CD4+ lymphocyte count at HPV testg, median (IQR) 528 (326–827) 512 (309–679) 433 (309–631) 398 (251–549)a, b 436 (296–679)
HIV RNA <400 copies/mlh, n (%) 27 (42.2) 63 (47.0) 74 (40.4) 62 (34.3) 226 (40.2)
Total months since cART initiation at HPV test, median (IQR) 1.65 (0–12.5) 2.5 (0–15.1) 3.6 (0–16.9) 2.0 (0–13.5) 2.5 (0–14.13)
Total number of low-risk HPV types detected, median (IQR) 0 1 (1–2) 1 (1–2) 2 (1–3)a 1 (0–2)
HPV 16 or 18 detected, n (%) 0 0 42 (23.0) 82 (45.3)d 122 (22.1)
Cytology results, n (%)      
Any Abnormal 7 (10.9) 22 (16.4) 53 (24.0)c 84 (46.4)c, d 166 (29.5)
ASC-US or AGC 5 (7.8) 14 (10.5) 19 (10.4) 26 (14.4) 64 (11.4)
LSIL 1 (1.6) 7 (5.2) 30 (16.4)c 47 (26.0)c, d 85 (15.1)
HSIL 1 (1.6) 1 (0.8) 4 (2.2) 10 (5.5) 16 (2.9)
Cancer 0 0 0 1 (0.6) 1 (0.2)
  1. aRank sum test of comparison with one HR HPV group p < 0.05
  2. bRank sum test of comparison with no HPV group p < 0.05
  3. cFisher exact test of comparison with no HPV group p < 0.05
  4. dFisher exact test of comparison with one HR HPV group p < 0.05
  5. eThere were 6 women in total missing tobacco use data
  6. fThere were 5 women in total missing CD4+ lymphocyte nadir data
  7. gThere were a total of 37 women with missing CD4+ lymphocyte data at the time of HPV exam
  8. hThere were 63 women with missing HIV RNA data at the time of HPV exam
  9. Abbreviations used
  10. IQR: interquartile range
  11. cART: combination antiretroviral therapy
  12. ASC-US: atypical squamous cells of unknown significance
  13. AGC: atypical glandular cells
  14. LSIL: low-grade squamous intraepithelial lesion
  15. HSIL: high-grade squamous intraepithelial lesion